Cardiol Expands Phase III MAVERIC Trial in Pericarditis Care
Toronto, Ontario, Canada, September 23, 2026 Cardiol Therapeutics has announced that its pivotal Phase III MAVERIC clinical trial evaluating...
cardiovascular disease
Advertisement
Marea Therapeutics and Lisata to Present MAR001 Phase 2b Data
SOUTH SAN FRANCISCO, Calif. and LIBERTY CORNER, N.J. — September 24, 2026 Marea Therapeutics, a subsidiary of Lisata Therapeutics,...
Wave Initiates Phase 2a WVE-007 Combination Trial for Obesity
CAMBRIDGE, Mass. — September 23, 2026 Wave Life Sciences announced the initiation of a Phase 2a clinical trial evaluating...
Zealand Pharma Initiates Phase 3 ZUPREME Program for Petrelintide
COPENHAGEN, Denmark — September 22, 2026 Zealand Pharma announced the initiation of the global registrational Phase 3a ZUPREME program...
Novo Nordisk to Share New Cardiometabolic Data at EASD 2026!
Bagsværd, Denmark, September 16, 2026 Novo Nordisk has announced that it will present new clinical and real-world evidence spanning...
Advertisements
Skyhawk Therapeutics Reports 15-Month SKY-0515 Results
Waltham, Massachusetts, U.S., September 16, 2026 Skyhawk Therapeutics has announced final 15-month results from its Phase 1/2 clinical trial...
Longeveron Reports ELPIS II Results for Laromestrocel
MIAMI — September 16, 2026 Longeveron Inc. announced topline results from its Phase 2b ELPIS II clinical trial evaluating...
HDT Bio Leads ARPA-H Program for Personalized RNA
Seattle, Washington, U.S., September 15, 2026 HDT Bio Corp. has received an ARPA-H GIVE award to lead the development...
Cogent Biosciences Gains FDA Acceptance for Bezuclastinibm
WALTHAM, Mass. and BOULDER, Colo. — September 15, 2026 Cogent Biosciences, Inc. announced that the U.S. Food and Drug...
Thryv Therapeutics Advances THRV-1268 for Heart Failure Care
Toronto, Ontario, Canada, September 16, 2026 Thryv Therapeutics has announced the publication of new research in JACC: Heart Failure...
Advertisement
